APA

Yeh C., Chang Y., Su Y., Shin-Shian Hsu D., Cheng C., Wu R., Chung Y., Chiang K., Yeh T., Lu M., Liu C., Mu-Hsin Chang P., Chen M., Huang C. F., Hsiao M. & Chen M. (2017). Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. : Oncotarget.

Chicago

Yeh Chun-Nan, Chang Yu-Chan, Su Yeu, Shin-Shian Hsu Dennis, Cheng Chi-Tung, Wu Ren-Chin, Chung Yi-Hsiu, Chiang Kun-Chun, Yeh Ta-Sen, Lu Meng-Lun, Liu Chun-Yu, Mu-Hsin Chang Peter, Chen Ming-Han, Huang Chi-Ying F, Hsiao Michael and Chen Ming-Huang. 2017. Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. : Oncotarget.

Harvard

Yeh C., Chang Y., Su Y., Shin-Shian Hsu D., Cheng C., Wu R., Chung Y., Chiang K., Yeh T., Lu M., Liu C., Mu-Hsin Chang P., Chen M., Huang C. F., Hsiao M. and Chen M. (2017). Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. : Oncotarget.

MLA

Yeh Chun-Nan, Chang Yu-Chan, Su Yeu, Shin-Shian Hsu Dennis, Cheng Chi-Tung, Wu Ren-Chin, Chung Yi-Hsiu, Chiang Kun-Chun, Yeh Ta-Sen, Lu Meng-Lun, Liu Chun-Yu, Mu-Hsin Chang Peter, Chen Ming-Han, Huang Chi-Ying F, Hsiao Michael and Chen Ming-Huang. Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. : Oncotarget. 2017.